{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-017857","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.765011+00:00","generated_at":"2026-06-15T22:48:47.975956+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Relay Therapeutics Q1 net loss $94.2M; cash $937.8M; RLY-2608 shows no Grade 3 hyperglycemia","bullets":["Net loss of $94.2M ($0.78 per share) vs $62.0M ($0.57) in Q1 2022; R&D expense $82.8M up from $51.7M.","Cash, equivalents and investments $937.8M vs ~$1B at Dec 31 2022; expected to fund operations into 2025.","Initial RLY-2608 data at AACR: no Grade 3 hyperglycemia/rash/diarrhea at target exposures; one confirmed partial response in breast cancer patient after cut-off.","RLY-5836 first-in-human trial initiated in April 2023 for PIK3CA-mutant solid tumors; RLY-2139 candidate selected, clinical start early 2024.","Full RLY-4008 dose escalation data accepted at ASCO 2023; expansion cohorts for RLY-2608 planned H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-017857","json":"https://secwatch.observer/filing/0000950170-23-017857.json","markdown":"https://secwatch.observer/filing/0000950170-23-017857.md","text":"https://secwatch.observer/filing/0000950170-23-017857.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000095017023017857/0000950170-23-017857-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000095017023017857/rlay-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:48:47.975956+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7050453fcf2d010f7c15133438f4bf6244a4975f","claim":"Relay Therapeutics, Inc. reported the first quarter of 2023 results: net income $94.2 million, EPS $0.78.","evidence_excerpt":"Net loss was $94.2 million for the first quarter of 2023, or a net loss per share of $0.78, as compared to a net loss of $62.0 million for the first quarter of 2022, or a net loss per share of $0.57.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1812364/000095017023017857/0000950170-23-017857-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2023"},{"label":"Net income","value":"$94.2 million"},{"label":"EPS","value":"$0.78"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}